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Abstract
Background: Brucellosis is one of the most severe widespread zoonoses caused by the Gram-negative bacterium
Brucella species. The diagnosis and clinical assessment of human brucellosis are very important for the management
of patients, while there is a lack of effective methods to detect Brucellae. Classical culture of Brucella species is time
consuming and often fails. A simple and sensitive assay is needed for diagnosis of Brucella infection and monitoring
of treatment in man.
Methods: Blood samples and peripheral blood mononuclear cells (PBMCs) were collected from 154 patients
hospitalized for brucellosis. Brucella antibodies were detected by Rose Bengal Plate Test (RBPT), Standard Tube
Agglutination Test (SAT) and enzyme-linked immunosorbent assay (ELISA). Intracellular Brucellae were detected by
blood culture and immunofluorescence staining (IFS).
Results: Among 154 brucellosis patients, 59.7% (92/154) were antibody reactive by RBPT, 81.8% (126/154) by SAT
and 95.5% (147/154) by ELISA, respectively. Only 3.2% (5/154) of patient blood samples resulted in positive Brucella
culture, while 68.8% (106/154) carried IFS detectable Brucella antigens in PBMCs. Gender (P = 0.01) but not age
(P > 0.05) was a significant risk factor. The frequency of intracellular Brucella antigens was similar between patients
receiving different treatment regimens (P > 0.05). However, a significant decrease of intracellular Brucellae was
observed only in patients with acute brucellosis after the third course of treatment (P < 0.05), suggesting that
current regimens to treat chronic brucellosis were not effective.
Conclusions: IFS appears a sensitive assay for detection of Brucella antigens in PBMCs and could be used for
diagnosis and therapeutic monitoring of brucellosis in clinical practice.
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Introduction
Brucellosis is one of the most severe widespread zoonoses
in the developing world and is caused by the Gram-
negative bacterium Brucella species [1]. Intracellular Bru-
cella spp. is often detected in chronic disease, and usually
persists lifelong [2]. Clinical manifestations of human
brucellosis include fever, profuse sweating, joint and
muscle pain, hepatomegaly and splenomegaly, osteomyelitis,
arthritis and sacroiliitis, etc., severely impacting patient’s
quality of life [3–5]. Early diagnosis and treatment of brucel-
losis could significantly improve patient prognosis. Isolation
of the organism from cultured blood samples was the
diagnostic gold standard. Meanwhile serological tests
were used to diagnose human brucellosis together with
patient’s clinical and epidemiological history. Culture
requires 3–5 days to develop visible colonies, but Bru-
cella spp. grows slowly, so it may take as long as over 2
weeks to obtain a definitive result. Due to its pathogen-
icity, a biosafety level 3 laboratory (BSL-3) is mandatory
when handling Brucellae [6]. A faster and safer brucel-
losis laboratory testing method should be established,
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especially in developing countries. In this study, previ-
ously developed immunofluorescence cell staining (IFS)
was utilized to detect intracellular bacteria [7, 8] and
was applied for diagnosis and monitoring of patients
infected with Brucellae.
Materials and methods
Blood samples
A number of 154 blood samples were collected from bru-
cellosis patients at the General Hospital of Agricultural
Reclamation Bureau, Harbin, Heilongjiang, China. All pa-
tients were initially diagnosed with brucellosis by clinical
examination in combination with serological testing and
bacterial culture, including the Rose Bengal Plate Test
(RBPT), the Standard Tube Agglutination Test (SAT) and
blood culture. Peripheral blood mononuclear cells (PBMCs)
were prepared for detection of intracellular Brucellae ac-
cording to the manufacturer’s instructions (Ficoll Pague
PLUS, GE Healthcare Life Sciences).
The control blood samples were collected in Guangzhou
blood center, Guangdong province where brucellosis is
non-endemic. Blood donors passed the predonation ques-
tionnaire, including lack of fever but no question addressed
brucellosis history. The blood samples were routinely
screened with two different enzyme immunoassays for
HBsAg and antibodies to HCV, HIV-1/2, and syphilis
[9, 10]. Thirty-six blood donors with negative sero-
logic tests and normal ALT level were selected to test
for Brucella infection.
Immunofluorescence staining (IFS) of PBMCs
Intracellular Brucellae in patient’s PBMCs were detected
by IFS [7]. PBMCs were isolated from 3ml of fresh
EDTA venous blood by Ficoll Hypaque, then transferred
in a culture plate for 2 h in order to let cells attach. Sec-
ondly, cells attached on the plate were fixed and indi-
vidually incubated with a monoclonal antibody (mAb) as
primary antibody, such as mAb 2C1, 5H3, 2A4 or 5A5
against Bp26 or Omp31 protein of Brucellae [7, 8]. MAb
2E12 to HCV NS3 was used as negative control [11].
Alexa Fluor 594-conjugated goat anti-mouse secondary
IgG (H + L) (Invitrogen China Limited, Guangzhou,
China) or Alexa Fluor 594-conjugated Affinipure Goat
Anti-Mouse IgG + IgM (H + L) (Jackson ImmunoRe-
search Laboratories, Inc., USA) were used as secondary
antibody. The stained cells were examined by a Nikon-
Labophot photomicroscope with the epifluorescence
attachment EF-D (Nikon, Garden City, NY, USA).
Brucella blood culture
Five to 10 ml of peripheral blood were cultured for Bru-
cellae using an automatic blood culture system (Biomer-
ieux Co. Ltd., Bact/ALERT 3D 60, Lyon, France) with an
average culture time of 5–7 days, as previously described
[12]. Visible bacteria colonies were identified using auto-
matic microbial identification machine (Biomerieux Co.
Ltd., VITEK 2 COMPACT 30).
Serologic assays
Patients’ sera were retrospectively re-tested by RBPT
and SAT according to the manufacturer’s instructions
(Biovaccine Co., Ltd., Harbin Pharmaceutical Group,
Harbin, China). Antibody titer of patient’s sera tested
with SAT equal to or over 1:100 indicated a diagnosis of
Brucellosis in addition to chronic patients with epi-
demiological exposure history carrying low titer antibody
such as 1:50. Sera were also tested with an enzyme-
linked immunosorbent assay (ELISA) (Brucella IgG
ELISA Kit, Neobioscience Technology CO., LTD).
Treatment of human brucellosis
Brucellosis patients were treated with a combination of
at least two compatible drugs according to presentation
and condition. Intravenous treatment included Etimicin
(100 mg ivgtt, twice), Enoxacin (0.2 g ivgtt, twice), Levo-
floxacin (0.6 g ivgtt, once), Ceftazidime (3 g ivgtt, twice)
or Cefperazone-Sulbactam (3 g ivgtt, twice), together
with a drug taken orally, including Rifampicin (0.45–0.6
g p.o., once in the morning) or Doxycycline (0.1 g p.o.,
twice). Some volunteer patients already on combined
drug treatment additionally received immune enhancing
drugs such as Thymopeptides and Placental Polypeptides
(Guizhou Taibang Biological Products Co., LTD., Chin-
ese Food and Drug Administration (CFDA) approval
number: H20046260). Acute brucellosis was treated in
hospital with multiple standard 20 days courses of treat-
ment separated by an interval of 10 days.
Statistical analysis
Computer software (SPSS, Version 21.0, SPSS, Inc.,
Chicago, IL) was used for statistical analysis. Experi-
mental data was analyzed by chi-square test and T test.
Abnormal distribution data was analyzed by multiple-
sample nonparametric test. A P value of less than 0.05
was considered significant.
Results
Characterization of patients with Brucella infection
A total of 154 patients were enrolled in this study (Add-
itional file 1: Table S1). Males were 114 (74.0%) and 40
(26.0%) were female, ranging in age between 3 to 73
years with a mean age of 43.4 ± 13.5 years. Patients were
stratified in two clinical groups: acute phase (with symp-
toms for less than 6 months) and chronic phase (with
symptoms for more than 6months). There were 68
acute and 86 chronic cases, respectively. The epidemio-
logic investigations indicated that 139 patients (90.3%)
experienced close contact with animals, six patients
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(3.90%) had consumed raw meat or dairy products, and
the remaining nine patients did not report at risk cir-
cumstances. Occupations were 25 (16.20%) livestock
keepers, 73 (47.40%) farmers, 44 (28.57%) veterinarians,
6 (3.9%) students, 4 (2.60%) small business owners and 2
(1.30%) breeders (Fig. 1).
Simultaneously, more than 70% patients presented four
typical clinical symptoms: fatigue, joint pain, sweating and
fever (Fig. 2). In addition, backache, hepatalgia, headache,
muscular soreness and orchitis appeared relatively
common. Only 10 patients experienced nausea, vomit-
ing, anorexia and other symptoms (Fig. 2). Brucellosis
was diagnosed by a combination of clinical examination
and laboratory testing with RBPT and SAT at admis-
sion to hospital. Some of these patients had received
antimicrobial treatment, while others remained un-
treated (Additional file 1: Table S1).
Detection of Brucella antigens by IFS in PBMCs of treated
brucellosis patients
Brucellae are known for persistently residing within phago-
cytes in chronic brucellosis patients and orchestrating di-
verse immune evasion strategies from this niche [4, 13].
Once infected with Brucellae, most patients show symp-
toms during the acute phase and could be either cured or
progressing to chronicity with long symptomatic periods.
In this study, the PBMCs from 154 patients and 36 blood
donors were tested for intracellular Brucellae by IFS with
mAbs 2C1, 5H3, 2A4 and 5A5 specific to either Brucella
BP26 or OMP31 protein, respectively. Pictures of visible
intracellular Brucellae were taken with a fluorescence
microscope with appropriate filters (Fig. 3). Overall, 68.8%
(106/154) patients carried intra-PBMC bacteria (Table 1),
while all 36 blood donors were negative by IFS.
Comparison of detection rates between antibody and
antigen tests in hospitalized patients with brucellosis
Blood samples from 154 brucellosis patients were re-tested
during hospitalization. Data showed 59.7% (92/154) of blood
samples antibody reactive with RBPT, 81.8% (126/154) with
SAT, and 96.1% (148/154) with ELISA, respectively. Only
3.2% (5/154) of bacterium blood cultures were positive com-
pared with 68.8% (106/154) PBMCs Brucella antigen positive
by IFS. Moreover, 22 (14.3%) patients were negative with
both IFS and RBPT, and 9 (5.8%) with both IFS and SAT.
Antigen detection was negative with both IFS and culture in
47 patients (30.5%). Altogether only one patient (0.6%) was
negative with all serologic and antigen tests (Table 1).
Compared with antibody detection, 72.2% (65/90) sam-
ples were positive by IFS and reacted with all three sero-
logic methods (Table 2). Several cases were negative for
one or two serologic tests but positive for IFS. For example,
68% (17/25) samples positive with IFS were negative for
both RBPT and SAT. Among ELISA or RBPT negative
samples, 50% (1/2) or 63.6% (21/33) reacted with IFS, re-
spectively (Table 2). Only two patients (1.3%) were antibody
test negative but positive for bacterial antigens by IFS
(Table 1), suggesting that patients with persistent Brucella
in PBMCs may lose detectable antibody reactivity. Patients
with negative IFS (47/154 or 30.5%, Table 1) might have ef-
fectively eliminated the bacteria as a result of treatment.
Association of IFS detection with potential factors of
brucellosis
We examined the correlation between detection rate of
Brucellae and multiple potentially associated factors. Only
gender was significantly correlated with IFS detection
(P = 0.01), others factors such as the age, therapeutic man-
agement and stage of disease were unrelated to detectable
Fig. 1 Baseline demographics of patients with brucellosis. a-e Brucellosis patients were classified by their gender, age, disease status,
epidemiology history and occupation, respectively
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intracellular Brucellae (P > 0.05) (Table 3). There was no
significant difference in the rate of PBMC bacterium car-
riers between patients with acute or chronic brucellosis
(70.6 and 67.4%, respectively, P > 0.05). The IFS rate of
intracellular Brucellae detection in PBMCs was not signifi-
cantly reduced by any particular treatment regimen.
Treated patients were 68.7% IFS positive, nearly equal to
the pre-treatment 68.8%. Positive PBMC rates remained
similar when patients received antimicrobial drugs alone
(79.5%) or drugs combined with immune enhancing
agents (63.8%) (Table 3).
Significance of intracellular Brucellae detection in
monitoring therapeutic efficacy in acute or chronic
brucellosis patients
Among 154 brucellosis patients, 68 were classified as
acute phase of infection. The antibody or antigen detec-
tion showed that 98.5% (67/68) and 70.6% (48/68) were
positive with SAT or IFS, respectively (Table 3). Treated
acute brucelloses presented 84.4% positive IFS after the
first two treatment courses and 53.8% positive test after
the third course, suggesting 30% a significant difference
of therapeutic efficacy (P = 0.011). This difference was
not observed with antibody detection by SAT and ELISA
(Table 4), indicating that reactive antibody against Bru-
cellae might persist for long period after bacteria had
been eliminated. The completion of a third therapeutic
course appeared as a key element to ensure a favorable
outcome. Generally most acute brucellosis patients were
discharged from hospital after the third course of ther-
apy, although more than half of them (53.8%) still
carried intra-PBMC Brucellae (Table 4), suggesting that
further treatment might remain indicated. In contrast,
patients with chronic brucellosis showed no difference
(P > 0.05) between SAT or ELISA for antibody and IFS
for bacteria, irrespective of treatment regimen (Table 4).
Discussion
Brucellosis is a highly contagious zoonosis. Epidemiological
study showed that the main risk factors included contacts
with infected animals, ingestion of unpasteurized milk and
dairy products. Recently, a review indicated that 24.6% of
590 brucellosis patients, in Xin Jiang province of China,
were infected through consumption of raw and uncooked
animal products. Among 154 patients ranging between 3
to 73 years of both genders in this study (Fig. 1 and Add-
itional File 1: Table S1), only 3.9% were infected through
eating raw or uncooked animal products. This percentage
was lower than reported in other countries, such as 62.6–
94.6% in Turkey and 79.1% in Iran [12], presumably indi-
cating different traditional eating habits. Additionally, most
patients in the present study (approximately 90.3%) were
infected through close contacts with animals as previously
described [12], and their occupations did carry risk of in-
fection [14, 15]. Gender (male 74.0% and female 26.0%)
was correlated with the rate of positive IFS, but people
working as farmer, breeder or veterinarian, were mostly
male. There was a common cause of brucellosis transmis-
sion in Heilongjiang and Xinjiang provinces that drew at-
tention to the prevention of human brucellosis. Animals
are frequently transported across China [16] and more and
more Chinese people travel across the country. Moreover,
Fig. 2 Clinical features of patients with brucellosis
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many people eat undercooked local dishes, such as roast
lamb and other related food in Xinjiang, Inner Mongolia
and other northern areas of China. These Northern prov-
inces are the main epidemic areas of brucellosis.
Most clinical symptoms of human brucellosis are un-
specific. In this study 70% of patients experienced fa-
tigue, arthralgia, hyperhydrosis and fever (Fig. 2). Less
frequent were backache, hepatalgia, headache, muscular
Fig. 3 Detection of Brucella antigen in PBMCs by IFS with mAbs. (a, b, c, e, f, g) Brucellosis patients’ PBMCs were stained by IFS with mAbs 2C1
and 5H3 specific to Omp31 antigens, 2A4 and 5A5 specific to Bp26 antigens of Brucella species, individually; (d, h) The NS3 antibody 2E12 for
HCV was reactive as negative control. IFS stained cells were examined by a Nikon Labophot photomicroscope under white or fluorescent light.
Scale bars = 200 μm
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soreness and orchitis that appeared relatively unspecific.
Few patients had other symptoms including nausea,
vomiting and decreased appetite. Considering the lack
of typical clinical manifestations and extremely slow
growth of Brucellae, it was difficult to distinguish bru-
cellosis from other sickness with similar clinical symp-
toms contributing to misdiagnosis and delay in diagnosis
and therapy [14, 15]. In addition, relapse of brucellosis
was sometimes difficult to diagnose, considering the fre-
quency of false negative blood cultures (definite diagnosis
of brucellosis), and how ubiquitous symptoms were [17].
Among 154 patients in our study, only 3.2% blood samples
were positive by culture (Table 1), a percentage much
lower than in other reports [2] contrasting with 68.8%
detection of intra-cellular Brucella antigens. Due to high
infectivity of Brucellae, blood culture carries a risk to la-
boratory staff. The diagnosis of brucellosis traditionally re-
lies on serologic testing, such as RBPT, SAT and ELISA
and other methods. Each of these serologic assays having
relatively poor performance a direct assay for Brucella
antigen is needed for accurate diagnosis. In this study 154
patients were retrospectively found positive 59.7% with
RBPT, 81.8% with SAT and 96.1% with ELISA, respect-
ively (Table 1), consistent with previous reports that
ELISA had superior performance. It was therefore the rec-
ommended method for the diagnosis of infection with
Brucella abortus, melitensis and suis by OIE [18] that may
replace other antibody tests in the future [19]. Addition-
ally, we found 47 patients (30.5%) negative with IFS but
positive by antibody detection whose antibody persisted
for prolonged periods of time (Table 1). However, chronic
patients were frequently negative for SAT (27/86, 31.4%)
but few in acute patients (1/68, 1.5%) suggesting that anti-
body reactivity might become undetectable as patients
progressed to chronic infection (Table 4). For example, we
observed several cases negative for one or more sero-
logic tests but positive for IFS (Table 2). In addition,
68% (17/25) of both SAT and RBPT negative patients
remained positive by IFS (Table 2). Treated patients with
acute or chronic brucellosis were not significantly differ-
ent in terms of antibody detection with SAT and ELISA,
irrespective of treatment courses (Table 4). Therefore,
serologic tests appeared rather unsuitable for patient
follow-up, and were not always informative for latent car-
riers of Brucella infection [20–22]. Antibody reactivity or
titer were not reliable laboratory tests to estimate the effi-
cacy of treatment or passage to chronicity. During the
course of therapy, physicians might estimate treatment ef-
ficacy according to persistence of symptoms and presence
of intra-cellular Brucellae detected by IFS.
For this purpose, IFS was developed to detect Brucel-
lae [7] and was extensively used in this study. IFS
Table 1 Reactivity of Brucella antibody or antigen in brucellosis
patients
Reactive Number (%) IFS
+ (%) - (%)
Patient number 154 (100) 106 (68.8) 48 (31.2)
RBPT + 92 (59.7) 66 (42.8) 26 (16.9)
– 62 (40.3) 40 (26) 22 (14.3)
SAT + 126 (81.8) 87 (56.5) 39 (25.3)
– 28 (18.1) 19 (12.3) 9 (5.8)
ELISA + 148 (96.1) 103 (66.9) 45 (29.2)
– 6 (3.8) 3 (1.9) 3 (1.9)
Totala + 151 (98) 104 (67.5) 47 (30.5)
– 3 (1.9) 2 (1.3) 1 (0.6)
Bacterial Culture + 5 (3.2) 4 (2.6) 1 (0.6)
– 149 (96.8) 102 (66.3) 47 (30.5)
aCompiled results of three serological testing methods and IFS
Table 2 Comparison of detection rate between Brucella antigen
and antibody
RBPT SAT ELISA Intra-cellular Brucella antigen
by IFS
Patient number
Positive (%) Negative (%) Total
Pos Pos Pos 65 (72.2) 25 (27.8) 90
Pos Pos Neg 1 (50) 1 (50) 2
Pos Neg Pos 0 0 0
Neg Pos Pos 21 (63.6) 12 (36.4) 33
Pos Neg Neg 0 0 0
Neg Pos Neg 0 1 (100) 1
Neg Neg Pos 17 (68) 8 (32) 25
Neg Neg Neg 2 (66.7) 1 (33.3) 3
Overall 106 (68.8) 48 (31.2) 154
Table 3 Factors potentially impacting IFS detection of human
brucellosis
IFS (Nb/%) Total Ρ value
+ –
Gender* Male 72 (63.2%) 42 (36.8%) 114 0.01
Female 34 (85%) 6 (15%) 40
Status Acute 48 (70.6%) 20 (29.4%) 68 0.676
Chronic 58 (67.4%) 28 (32.6%) 86
Treatment Treated 90 (68.7%) 41 (31.3%) 131 0.934
Untreated 16 (69.9%) 7 (30.4%) 23
Therapy
regimen#Δ
Routine 31 (79.5%) 8 (20.5%) 39 0.088
Addition 44 (63.8%) 25 (36.2%) 69
Mean age 43.4 ±
13.5
43.9
(68.8%)
42.2
(31.2%)
154 0.472
*P value of less than 0.05 was considered significant
#Routine therapy regimen indicated the standard antibiotic treatment;
Additional therapy regimen indicated the standard antibiotic treatment
additionally receiving immune enhancing drugs
ΔTherapy regimen situation of 23 treated brucellosis patients was missing
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identified 68.8% (106/154) of patient PBMCs carrying
the bacterial antigen massively increasing direct detec-
tion of Brucellae in patients’ PBMCs without the specifi-
city issues inherent to serologic assays. The detection
rate of Brucella antigens was not related to patient’s age
or treatment regimen (P > 0.05). The significant infec-
tion risk related to gender (P = 0.01) was unsurprising
since the male population carries most occupational
or professional activities involving close contact with
infected animals.
The frequency of intracellular Brucellae in PBMCs of
infected patients was similar whether they were in acute
or chronic state or receiving different treatment regi-
mens (P > 0.05). It is well known that brucellosis seldom
recovers completely, which coincides with high detection
rate by IFS in 69.9% of untreated brucellosis and 68.7%
of treated patients (Table 3). Once the infection becomes
chronic, patients are likely to keep carrying Brucellae for
their whole life, as happened to our 58 chronic patients
ranging in age from 4 to 73 years who received more
than three courses of therapy but a majority (67.2%)
remained IFS positive (Table 4). At the chronic stage test
positivity was even higher, 62.1% by SAT or 94.8% by
ELISA (Table 4). Unfortunately the study was strictly
cross-sectional since sequential samples could only be
obtained for two patients.
Despite the lack of correlation with positive culture,
our IFS intra-cellular Brucellae antigen strongly suggests
the prolonged persistence of the bacterium in chronic
cases, irrespective of therapy (Fig. 3). It was previously
reported that patients had a tendency toward chronicity
and persistence, becoming a granulomatous disease cap-
able of affecting any organ [2, 23]. However, it would be
critical to determine whether or not the 31.2% patients
with negative IFS were effectively free of the infection ei-
ther spontaneously or through combination therapy. An-
swer to this question would require sequential IFS testing
of patients with chronic infection with and without symp-
toms, with and without therapy. The 67.4% (58/86) of pa-
tients with chronic infection positive by IFS illustrate the
difficulty of eliminating intracellular Brucellae and the
poor efficacy of current treatments for chronic brucellosis.
This situation is supported by previous description of Bru-
cella chronic infection [10, 24]. There is a need for novel
drugs to improve the efficacy of treatments that might be
monitored with the IFS assay.
The poor therapeutic outcome of therapy in chronic
brucellosis might be mitigated by the data obtained in
acute infection treatment. While antibody remained
positive, all except one patient having received two
courses of treatment had significantly higher prevalence
of positive IFS assay than those having received a third
course of therapy in hospital (Table 4). Such difference
observed in relatively small groups of patients studied
transversally would need confirmation in a proper longi-
tudinal study. The IFS assay might, at this point, repre-
sent the most suitable means for evaluating brucellosis
treatment. It might be equally important to combine the
IFS with other antibody tests. In this study, only 14.3%
(22/154) were negative with both IFS and RBPT, and
5.8% (9/154) with both IFS and SAT. Compared to 3.2%
positive rate of blood culture, 102/149 patients (66.3%)
carried PBMCs with detectable bacteria with the IFS
technique (Table 1), indicating a massive improvement
in the detection of intracellular Brucellae. Considering
the biosafety requirements, the time-consuming aspect
of culture of Brucella strains, IFS detection of intracellu-
lar Brucellae might be a better diagnostic or monitoring
test of brucellosis treatment in clinical practice.
Several patients in the study received immunopoten-
tiators in addition to the standard antibiotic treatment.
There was no clear benefit of this approach evidenced
Table 4 Comparison of antibody and antigen detection rates in
acute or chronic brucellosis
Phase Therapy
course
Reactivity (Nb/%) Total P value
Intragroup+ –
Acute SAT 0 10 (100%) 0 10 0.467
1–2 31 (96.9%) 1 (3.1%) 32
≥3 26 (100%) 0 26
Overall 67 (98.5%) 1 (1.5%) 68
ELISA 0 9 (90%) 1 (10%) 10 0.209
1–2 30 (93.8%) 2 (6.2%) 32
≥3 26 (100%) 0 26
Overall 65 (95.6%) 3 (4.4%) 68
IFS 0 7 (70%) 3 (30%) 10 0.038*
1–2 27 (84.4%) 5 (15.6%) 32
≥3 14 (53.8%) 12 (46.2%) 26
Overall 48 (70.6%) 20 (29.4%) 68
Chronic SAT 0 12 (92.3%) 1 (7.7%) 13 0.061
1–2 11 (73.3%) 4 (26.7%) 15
≥3 36 (62.1%) 22 (37.9%) 58
Overall 59 (68.6%) 27 (31.4%) 86
ELISA 0 13 (100%) 0 13 0.299
1–2 15 (100%) 0 15
≥3 55 (94.8%) 3 (5.2%) 58
Overall 83 (96.5%) 3 (3.5%) 86
IFS 0 9 (69.2%) 4 (30.8%) 13 0.988
1–2 10 (66.7%) 5 (33.3%) 15
≥3 39 (67.2%) 19 (32.8%) 58
Overall 58 (67.4%) 28 (32.6%) 86
*A significant difference was found in IFS detection rate among therapy
courses 0, 1–2 and ≥ 3 (P = 0.038), or between therapy courses 0–1-2 and ≥ 3
(P = 0.017) or 1–2 and ≥ 3 (P = 0.011) from acute phase of brucellosis patients
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by a significant decrease of IFS positivity (P > 0.05)
(Table 3). Some data in our earlier study may provide
some clue. Specifically, the ratio of regulatory T-
lymphocytes cell (CD3+CD4+Foxp3+ Treg) in PBMCs of
brucellosis patients determined by flow cytometry before
and after treatment showed that after the first and sec-
ond courses of treatment, the frequency of Foxp3+ Tregs
did not significantly change, as the frequency was still
higher than that in healthy populations, and there was
no significant difference between untreated and treated
groups [25]. After the third course of treatment (about
80 days), the frequency of Foxp3+ Tregs in the PBMCs
of acute brucellosis patients decreased to normal level of
healthy individuals, while the frequency of Foxp3+ Tregs
in immune enhancing treatment patients remained
higher. The data presented here suggests that the anti-
bacterial treatment of brucellosis should benefit of in-
cluding at least three courses of treatment and that the
IFS assay could be used to monitor therapeutic efficacy.
Conclusions
There is a lack of effective methods to detect Brucella
antigen and monitor treatment. In our study, 68.8%
PBMCs of brucellosis patients contained Brucellae de-
tectable by IFS. A significant decrease of intracellular
Brucellae detected by IFS was only observed in acute
brucellosis patients after the third course of treatment,
suggesting that 30% of therapeutic efficacy and current
therapeutic regimens were not effective for chronic bru-
cellosis. There was no significant difference in antibody
detection with SAT and ELISA, irrespective of treatment
courses. IFS appears a sensitive assay for detection of
Brucella antigen in PBMCs and could be used for diag-
nosis and therapeutic monitoring of brucellosis in clin-
ical practice.
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